Lanadelumab

Definition

A fully human immunoglobulin G1 (IgG1) monoclonal antibody against plasma kallikrein that can be used for the treatment of hereditary angioedema (HAE). Upon administration, lanadelumab targets and binds to plasma kallikrein, thereby inhibiting its proteolytic activity. This inhibits the cleavage of high-molecular-weight-kininogen (HMWK) into cleaved HMWK (cHMWK) and bradykinin. This in turn may prevent bradykinin-driven vasodilation, the resulting increase in vascular permeability, and the swelling and pain associated with HAE. This may also prevent or improve pulmonary edema not associated with HAE and improve the associated decrease in blood oxygen levels.

Also known as DX-2930, LANADELUMAB, Lanadelumab-flyo, SHP643, TAK-743, Takhzyro — per NCIT

Also identified as

• ATC B06AC05 per RXNORM
• NCIT NCIT:C166535 per NCIT
• SCTID 773956002 per RXNORM
• SCTID 773961000 per RXNORM
• UNII 2372V1TKXK per RXNORM

Indications